Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. J Infec Dis, 177, 310-319. presented at the 02/1998. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9466516. (1998).
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus Type 1. AIDS Res HumRetroviruses, 16, 2019-35. presented at the 2000.. (2000).